CRIS Current Research Information System

PALMERINI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.707
EU - Europa 4.448
AS - Asia 2.141
AF - Africa 256
SA - Sud America 20
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 13.592
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.678
GB - Regno Unito 1.205
IT - Italia 788
CN - Cina 723
DE - Germania 719
SE - Svezia 651
SG - Singapore 549
VN - Vietnam 463
IN - India 297
IE - Irlanda 236
RU - Federazione Russa 168
FR - Francia 164
ZA - Sudafrica 107
CH - Svizzera 95
EE - Estonia 95
UA - Ucraina 93
TG - Togo 79
CI - Costa d'Avorio 59
BG - Bulgaria 57
JO - Giordania 57
BE - Belgio 39
AT - Austria 30
FI - Finlandia 28
ES - Italia 17
JP - Giappone 17
CA - Canada 15
BR - Brasile 14
GR - Grecia 14
PL - Polonia 13
NL - Olanda 12
AU - Australia 10
MY - Malesia 10
BZ - Belize 7
IR - Iran 6
NO - Norvegia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
CR - Costa Rica 5
BD - Bangladesh 4
LB - Libano 4
NG - Nigeria 4
SC - Seychelles 4
UZ - Uzbekistan 4
CL - Cile 3
CZ - Repubblica Ceca 3
EU - Europa 3
HR - Croazia 3
DK - Danimarca 2
EG - Egitto 2
HU - Ungheria 2
MX - Messico 2
NZ - Nuova Zelanda 2
RO - Romania 2
SI - Slovenia 2
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
EC - Ecuador 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MU - Mauritius 1
PE - Perù 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TR - Turchia 1
Totale 13.592
Salva come PNG Salva come JPEG
Città #
Southend 1.104
Fairfield 860
Chandler 760
Ashburn 552
Woodbridge 463
Singapore 462
Wilmington 416
Seattle 359
Ann Arbor 346
Houston 341
Princeton 332
Cambridge 292
Dong Ket 261
Dublin 236
Bologna 112
Westminster 110
Nanjing 107
Padova 104
Santa Clara 100
Frankfurt am Main 99
Bern 86
Lomé 79
Berlin 77
Redmond 69
Beijing 66
Turin 66
San Diego 60
Abidjan 59
Saint Petersburg 58
Amman 57
Bremen 57
Sofia 51
Medford 48
Shenyang 45
Boardman 43
Falls Church 43
Des Moines 42
Milan 40
Dearborn 39
Jinan 39
Hebei 38
Brussels 37
Nanchang 34
Rome 32
San Jose 28
Changsha 26
Helsinki 25
Jacksonville 25
Los Angeles 23
Guangzhou 21
Norwalk 21
Vienna 21
Zhengzhou 19
Jiaxing 18
Tianjin 18
Hangzhou 16
New York 16
Redwood City 16
Bari 15
Shanghai 15
Florence 14
Haikou 13
Bühl 12
Mülheim 12
Olalla 12
Paris 12
Buffalo 11
Lanzhou 11
Las Vegas 11
London 11
Ningbo 11
Taiyuan 11
Tokyo 11
Wuhan 11
Chengdu 10
Kuban 10
San Francisco 10
Chicago 9
Modena 9
Taizhou 9
Catanzaro 8
Forlì 8
Kinde 8
Kuala Lumpur 8
São Paulo 8
Belize City 7
Fuzhou 7
Harbin 7
Hyderabad 7
Kilburn 7
Kunming 7
Naples 7
Oslo 6
Parma 6
Shenzhen 6
Toronto 6
Trieste 6
Albuquerque 5
Amsterdam 5
Barcelona 5
Totale 9.358
Salva come PNG Salva come JPEG
Nome #
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 200
CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: A single-institution morphological and molecular analysis of seven cases 169
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 161
Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? 155
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study 154
Advances in treatment for tenosynovial giant cell tumors 145
Case report: temozolomide induced partial response in a primary diffuse leptomeningeal gliomatosis patient. 139
Chondrosarcomas revisited. 137
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma 133
Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma 133
Diagnosis and prognosis for the Ewing family of tumors 132
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? 131
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors 131
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 129
Advanced chondrosarcomas: Role of chemotherapy and survival 129
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β 127
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone 127
A simple prognostic scoring system for non metastatic osteosarcoma of the extremity 126
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 124
Osteosarcoma follow-up: chest X-ray or computed tomography? 124
Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience 124
Pazopanib in relapsed osteosarcoma patients: report on 15 cases 123
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma 122
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age 121
Does MGMT (O6-methylguanine–DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)? 121
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas 121
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian sarcoma group study 119
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study 119
Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma 114
Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution 112
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma 108
SELNET clinical practice guidelines for soft tissue sarcoma and GIST 108
Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy 107
Ewing sarcoma in patients over 40 years of age: A prospective analysis of 31 patients treated at a single institution 107
ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2) 107
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1. 106
Phase ii study on lapatinib in advanced egfr-positive chordoma 105
Emerging therapeutic targets for synovial sarcoma 105
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial 104
A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy. 103
The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the italian Rizzoli experience. Impact on the future. 103
Osteosarcoma of the pelvis: A monoinstitutional experience in patients younger than 41 years 103
Synovial sarcoma: Is chemotaxis important to tumor progression? 102
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs 102
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 101
Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma 100
Palliative embolisation for advanced bone sarcomas. 100
CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338 100
Analysis of risk factors for central venous catheter-related complications: a prospective observational study in pediatric patients with bone sarcomas 99
Metastatic spread to bone: The role of chemotherapy 98
Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors 98
High dose ifosfamide in metastatic high-grade osteosarcoma, after failure of standard multimodal chemotherapy. 98
Delaying surgery for patients with a previous SARS-CoV-2 infection 98
Non-surgical treatment of chondrosarcoma: Current concepts and future perspectives 97
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma 97
Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients. 97
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS) 96
Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian sarcoma group/grupo español de investigación en sarcomas randomized clinical trial: Three versus five cycles of full-dose epirubicin plus ifosfamide 96
Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients 95
Neoadjuvant denosumab treatment of locally advanced giant cell tumor of bone (GCTB). 95
Extraskeletal myxoid chondrosarcoma: A retrospective analysis of 69 patients with localized disease and molecularly confirmed diagnosis. 95
Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. 95
Angiosarcoma of bone: A European Muscoloskeletal Oncology Society (EMSOS) multicenter, retrospective study 95
Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series. 94
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 94
Gemcitibine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy. 93
Predictive factors of histologic response to primary chemotherapy in patients with ewing sarcoma 92
null 92
Spontaneous regression of lung metastasis from osteosarcoma: A case report 91
High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. 90
null 89
Imaging in bone sarcomas. the chemotherapist's point of view 89
Management of angiosarcoma of bone 88
High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma? 88
A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS). 88
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: An Italian Sarcoma Group Trial ISG/OS-1 87
CIC-DUX4 Fusion-Positive Round Cell Sarcomas of Soft Tissue and Bone: Clinicopthologic and Molecular Analysis from a Single Institution 86
Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy 85
Osteoarticular allograft reconstruction for an angiosarcoma of the distal radius 85
Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: The rizzoli institute experience 85
PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma 85
FDG PET/CT IN PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED BONE SARCOMAS 85
Eribulin in advanced liposarcoma and leiomyosarcoma 85
Periosteal osteosarcoma: a single-institution experience. 85
Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). 83
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series 83
International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study. 82
Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study 82
Bone angiosarcoma: a retrospective analysis of 60 patients from two referral center 81
Temozolamide and irinotecan in metastatic Ewing sarcoma: An Italian Sarcoma Group and Royal Marsden Hospital join study. 81
A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian sarcoma group (ISG) study. 80
Long-term treatment of giant cell tumors of bone (GCTB) with denosumab: a two institutions 8-year experience. 80
Lapatinib in advanced chordoma: A phase II study. 80
Ewings sarcoma in patients over 40 years 79
Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati) 79
null 78
Synovial sarcoma: Retrospective analysis of 250 patients treated at a single institution 78
Primary Angiosarcoma of Bone: A Retrospective Analysis of 60 Patients From 2 Institutions 77
Osteosarcoma: Tra presente e futuro 77
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 77
Totale 10.455
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.187
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.387 0 0 0 171 299 271 382 408 368 235 96 157
2020/20211.973 292 115 30 61 355 41 44 118 144 124 82 567
2021/20222.826 231 70 166 150 326 160 68 251 164 223 489 528
2022/20233.336 356 470 247 423 225 238 121 188 525 125 207 211
2023/2024792 51 154 65 65 48 91 56 50 25 62 44 81
2024/20251.175 154 608 273 140 0 0 0 0 0 0 0 0
Totale 14.044